Vericel to Host Second-Quarter 2016 Earnings Webcast and Conference Call on August 8, 2016
August 01 2016 - 6:30AM
Vericel Corporation (NASDAQ:VCEL), a leading developer of
patient-specific expanded cellular therapies for the treatment of
severe diseases and conditions, today announced the following
webcast and conference call:
|
|
What: |
Vericel Corporation Second-Quarter 2016 Earnings
Call |
When: |
Monday, August 8, 2016 at 4:30pm (ET) |
Where: |
http://investors.vcel.com/events.cfm |
How: |
The conference call will be available live in the
Investors section of the Vericel website at
http://investors.vcel.com/events.cfm. Please access the site at
least 15 minutes prior to the scheduled start time in order to
download the required audio software if necessary. |
|
To participate in the live call by telephone,
please call (877) 312-5881 and reference Vericel Corporation
second-quarter 2016 investor conference call. If calling from
outside the U.S., please use the international phone number (253)
237-1173. |
|
|
If you are unable to participate in the live call, the webcast
will be available at
http://investors.vcel.com/events.cfm until August 8, 2017. A
replay of the call will also be available until 11:59 pm (EDT) on
August 12, 2016 by calling (855) 859-2056, or from outside the U.S.
(404) 537-3406. The conference ID is 57713501.
About Vericel CorporationVericel Corporation is
a leader in developing patient-specific expanded cellular therapies
for use in the treatment of patients with severe diseases and
conditions. The company markets two autologous cell therapy
products in the U.S.: Carticel® (autologous cultured chondrocytes),
an autologous chondrocyte implant for the treatment of cartilage
defects in the knee, and Epicel® (cultured epidermal autografts), a
permanent skin replacement for the treatment of patients with
deep-dermal or full-thickness burns comprising greater than or
equal to 30% of total body surface area. Vericel is also developing
MACI™, a third-generation autologous chondrocyte implant for the
treatment of cartilage defects in the knee, and ixmyelocel-T, a
patient-specific multicellular therapy for the treatment of
advanced heart failure due to ischemic dilated cardiomyopathy. For
more information, please visit the company’s website at
www.vcel.com.
CONTACT:
Chad Rubin
The Trout Group
crubin@troutgroup.com
(646) 378-2947
or
Lee Stern
The Trout Group
lstern@troutgroup.com
(646) 378-2922
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Apr 2024 to May 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From May 2023 to May 2024